Previous 10 | Next 10 |
Nurix Therapeutics (NASDAQ:NRIX) has recorded its worst-ever intraday decline after the company held its research & development (R&D) day on Thursday following a positive update from its ongoing Phase 1 trial for the cancer candidate NX-2127. Before the market opened, Nurix (NRIX) ann...
Gainers: Apyx Medical (APYX) +39%. Enochian Biosciences (ENOB) +17%. Concert Pharmaceuticals (CNCE) +14%. GeoVax Labs (GOVX) +14%. Liquidia (LQDA) +13%. Losers: NRx Pharmaceuticals (NRXP) -57%. Avadel Pharmaceuticals (AVDL) -44%. Nurix Therape...
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Pha...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally availa...
SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive...
SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced it will host a research & development (R&D) day for analysts and invest...
The following slide deck was published by Nurix Therapeutics, Inc. in conjunction with this event. For further details see: Nurix Therapeutics (NRIX) Investor Presentation -Slideshow
The shares of Nurix Therapeutics (NASDAQ:NRIX) have gained more than 10% on Friday to record the biggest intraday gain since October after the clinical-stage biotech announced preclinical data to support the clinical studies for its cancer therapies, NX-2127, and DeTIL-0255. NX-2127 is a...
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal models of adoptive cell therapy support the use of NX-0255 in the production o...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...